• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Innoviva Inc.

    5/4/26 5:00:42 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INVA alert in real time by email
    S-8 1 d143816ds8.htm S-8 S-8

    As filed with the Securities Exchange Commission on May 4, 2026

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    INNOVIVA, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   94-3265960
    (State or other jurisdiction of
    incorporation or organization)
     

    (I.R.S. Employer

    Identification No.)

     

    1350 Old Bayshore Highway, Suite 400

    Burlingame, California

      94010
    (Address of Principal Executive Offices)   (Zip Code)

    Innoviva, Inc. 2026 Equity Incentive Plan

    (Full title of the plan)

    Pavel Raifeld

    Chief Executive Officer

    Innoviva, Inc.

    1350 Old Bayshore Highway, Suite 400

    Burlingame, California 94010

    (Name and address of agent for service)

    (650) 238-9600

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    Jared Fertman

    Willkie Farr & Gallagher LLP

    787 Seventh Avenue

    New York, New York 10019

    (212) 728-8000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This registration statement on Form S-8 (this “Registration Statement”) is filed by Innoviva, Inc. (the “Company” or “Registrant”) to register for issuance (i) 9,000,000 shares of Common Stock, par value $0.01 per share, of the Registrant (“Common Stock”), which may be issued under the Innoviva, Inc. 2026 Equity Incentive Plan (the “2026 Plan”) and (ii) such additional shares that may become issuable in accordance with the 2026 Plan to prevent dilution resulting from any future stock splits, stock dividends or similar adjustments of the outstanding Common Stock. The 2026 Plan was adopted by the Company’s board of directors on March 16, 2026 and approved by the Company’s stockholders on May 4, 2026.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The document(s) containing the information specified in Part I of this Registration Statement will be sent or given to the participants under the 2026 Plan as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”). Such documents are not being filed with the Securities and Exchange Commission (the “Commission”) either as part of this Registration Statement prepared in accordance with the requirements of Form S-8 under the Securities Act or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents, filed with the Commission by the Company, are incorporated by reference into this Registration Statement:

     

      (a)

    the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed on February 25, 2026 (as amended on March 27, 2026);

     

      (b)

    the Company’s Definitive Proxy Statement on Schedule 14A, filed with the Commission on March 24, 2026 (as amended and supplemented); and

     

      (c)

    the description of the Company’s Common Stock, which is contained in Exhibit 4.9 to the Company’s Annual Report on Form 10-K filed on February 19, 2020, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), together with any amendment or any report subsequently filed with the Commission for the purpose of updating this description.

    In addition, all documents filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act, subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the securities offered hereby have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of the filing of such documents with the Commission; provided, however, that documents or portions thereof which are “furnished” and not “filed” in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement unless the Registrant expressly provides to the contrary that such document is incorporated by reference into this Registration Statement.


    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein (or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein) modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed to constitute a part of this Registration Statement except as so modified or superseded.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    Section 145 of the Delaware General Corporation Law authorizes a court to award or a corporation’s board of directors to grant indemnification to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities (including reimbursement for expenses incurred) arising under the Securities Act of 1933, as amended (the “Securities Act”). The Registrant’s Second Amended and Restated Bylaws (as amended and restated effective January 1, 2023) provide for mandatory indemnification of its directors and officers and those serving at the Registrant’s request as directors, officers, employees or agents of other organizations to the fullest extent authorized by the Delaware General Corporation Law, as the same exists or may hereafter be amended. The Registrant’s Second Amended and Restated Bylaws also provide for advancement of expenses incurred in defending any proceeding for which indemnification is applicable in advance of its final disposition, subject to an undertaking to repay such amounts if it is ultimately determined that the indemnitee is not entitled to indemnification. The rights to indemnification and advancement of expenses are contract rights under the Registrant’s Second Amended and Restated Bylaws. The Registrant’s Amended and Restated Certificate of Incorporation provides that, to the fullest extent permitted by the laws of the State of Delaware, no director of the Registrant shall be personally liable to the Registrant or its stockholders for monetary damages for breach of fiduciary duty as a director. This provision in the Amended and Restated Certificate of Incorporation does not eliminate the directors’ fiduciary duty, and in appropriate circumstances equitable remedies such as injunctive or other forms of non-monetary relief will remain available under Delaware law. In addition, each director will continue to be subject to liability for breach of the director’s duty of loyalty to the Registrant for acts or omissions not in good faith or involving intentional misconduct or knowing violations of law, for actions leading to improper personal benefit to the director, and for payment of dividends or approval of stock repurchases or redemptions that are unlawful under Delaware law. The provision also does not affect a director’s responsibilities under any other law, such as the federal securities laws or state or federal environmental laws. The Registrant has entered into indemnification agreements with its officers and directors. The indemnification agreements provide the Registrant’s officers and directors with further indemnification to the maximum extent permitted by the Delaware General Corporation Law. The Registrant maintains liability insurance for its directors and officers.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

    The following exhibits are filed herewith or are incorporated herein by reference.


              Incorporated by Reference     
    Exhibit
    Number
      

    Description

       Form    Exhibit    Filing
    Date/Period
    End Date
       Filed
    Herewith
      4.1    Amended and Restated Certificate of Incorporation    8-K    99.2    April 28, 2016   
      4.2    Amended and Restated Bylaws, amended and restated as of January 1, 2023    8-K    3.1    January 4, 2023   
      5.1    Opinion of Willkie Farr & Gallagher LLP             X
     23.1    Consent of Willkie Farr & Gallagher LLP (included as part of Exhibit 5.1)             X
     23.2    Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm             X
     24.1    Power of Attorney (included on the signature page of this Registration Statement)             X
     99.1    Innoviva, Inc. 2026 Equity Incentive Plan    DEF 14A    Appendix A    March 24, 2026   
    107*    Filing Fee Table             X

    Item 9. Undertakings.

     

    (a)

    The undersigned Registrant hereby undertakes:

     

    (1)

    To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)

    To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii)

    To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;

     

    (iii)

    To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Company pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (2)

    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.


    (b)

    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit, or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Burlingame, State of California on May 4, 2026.

     

    Innoviva, Inc.
    By:   /s/ Pavel Raifeld
        Pavel Raifeld
        Chief Executive Officer

    SIGNATURES AND POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Pavel Raifeld, as their true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Pavel Raifeld

    Pavel Raifeld

       Chief Executive Officer (Principal Executive Officer)   May 4, 2026

    /s/ Stephen Basso

    Stephen Basso

       Chief Financial Officer (Principal Financial Officer)   May 4, 2026

    /s/ Marianne Zhen

    Marianne Zhen

       Chief Accounting Officer (Principal Accounting Officer)   May 4, 2026

    /s/ Mark DiPaolo

    Mark DiPaolo, Esq.

       Director   May 4, 2026

    /s/ Jules Haimovitz

    Jules Haimovitz

       Director   May 4, 2026

    /s/ Sarah Schlesinger

    Sarah Schlesinger, M.D.

       Director   May 4, 2026

    /s/ Derek Small

    Derek Small

       Director   May 4, 2026
    Get the next $INVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INVA

    DatePrice TargetRatingAnalyst
    2/17/2026$35.00Buy
    BTIG Research
    9/30/2025$17.00Sell
    Goldman
    8/11/2025$45.00Outperform
    Oppenheimer
    7/14/2025$40.00Buy
    H.C. Wainwright
    7/11/2025$26.00Overweight
    Cantor Fitzgerald
    3/7/2025$55.00Sector Outperform
    Scotiabank
    6/18/2024Overweight
    Cantor Fitzgerald
    7/20/2022$16.00Neutral
    Goldman
    More analyst ratings

    $INVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Raifeld Pavel covered exercise/tax liability with 1,130 shares and was granted 1,123 shares, decreasing direct ownership by 0.00% to 285,929 units (SEC Form 4) to satisfy withholding tax

    4 - Innoviva, Inc. (0001080014) (Issuer)

    5/22/26 4:15:12 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Basso Stephen was granted 1,123 shares and covered exercise/tax liability with 559 shares, increasing direct ownership by 0.64% to 88,571 units (SEC Form 4) to satisfy withholding tax

    4 - Innoviva, Inc. (0001080014) (Issuer)

    5/22/26 4:15:16 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Zhen Marianne covered exercise/tax liability with 1,127 shares, decreasing direct ownership by 2% to 57,516 units (SEC Form 4) (for withholding tax)

    4 - Innoviva, Inc. (0001080014) (Issuer)

    5/22/26 4:15:09 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Innoviva with a new price target

    BTIG Research initiated coverage of Innoviva with a rating of Buy and set a new price target of $35.00

    2/17/26 7:51:08 AM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Innoviva with a new price target

    Goldman initiated coverage of Innoviva with a rating of Sell and set a new price target of $17.00

    9/30/25 8:55:53 AM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Innoviva with a new price target

    Oppenheimer initiated coverage of Innoviva with a rating of Outperform and set a new price target of $45.00

    8/11/25 10:03:31 AM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INVA
    SEC Filings

    View All

    SEC Form 8-K filed by Innoviva Inc.

    8-K - Innoviva, Inc. (0001080014) (Filer)

    5/18/26 4:21:36 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Innoviva Inc.

    SCHEDULE 13D/A - Innoviva, Inc. (0001080014) (Filed by)

    5/13/26 5:21:55 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Innoviva Inc.

    10-Q - Innoviva, Inc. (0001080014) (Filer)

    5/6/26 4:29:28 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Innoviva to Participate in Upcoming Investor Conferences

    Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference Format: Fireside chat Date: Monday, June 8, 2026 Time: 1:20 p.m. Eastern Time BTIG Infectious Disease Day Format: 1x1 meetings Date: Tuesday, June 16, 2026 A live webcast of the Goldman Sachs fireside chat can be accessed under "Ev

    6/1/26 11:00:00 AM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

    Generated $58.6 million in revenue from resilient royalties portfolio Achieved IST U.S. net product sales of $34.2 million for the first quarter, representing 29% year-over-year growth Significant value created across strategic healthcare asset portfolio Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2026, and highlighted select corporate progress and achievements.

    5/6/26 4:05:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

    Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 10:00 a.m. E.T. The conference will be held virtually. A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at https://investor.inva.com/presentati

    2/19/26 8:00:00 AM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INVA
    Leadership Updates

    Live Leadership Updates

    View All

    Innoviva Appoints Stephen Basso as Chief Financial Officer

    Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief Financial Officer, effective August 21, 2023. "We are excited to welcome Stephen to our executive leadership team and believe the Company will benefit greatly from his background and experience," said Pavel Raifeld, Chief Executive Officer of Innoviva. "I look forward to working with Stephen to advance our strategy and create shareholder value." Mr. Basso brings more than 30 years of experience in the financial services industry and financial leadership in the pharmaceutical ind

    8/25/23 4:52:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

    Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned healthcare leader Dr. Deborah L. Birx as Chief Executive Officer MARINA DEL REY, Calif., July 11, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen‐specific bacteriophage therapeutics for antibiotic‐resistant and difficult‐to‐treat bacterial infections, today announced that it has entered into a credit and security agreement with Innoviva Strategic Opportunities LLC, a wholly‐owned subsidiary of Innoviva, Inc. (NASDAQ:INVA) (collectively, "Innoviva"). The gross proceeds of t

    7/11/23 8:00:00 AM ET
    $ARMP
    $INVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Innoviva Announces Retirement of Board Chairman

    Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company") and George Bickerstaff, III, Chairman of the Board of Directors of the Company (the "Board") today announced that Mr. Bickerstaff would not stand for reelection at the Company's 2023 Annual Meeting. Following the Meeting, assuming that all other members of the Board are reelected, the Board will be comprised of six members. Mr. Bickerstaff indicated that he is stepping down from the Board to focus on other professional and philanthropic pursuits, which includes his role as chair of the Board of Trustees for the International Vaccine Institute. "Serving Innoviva as Board Chairman has been an honor," said Mr. Bickerstaff. "I am v

    4/28/23 5:30:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INVA
    Financials

    Live finance-specific insights

    View All

    Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

    Generated $58.6 million in revenue from resilient royalties portfolio Achieved IST U.S. net product sales of $34.2 million for the first quarter, representing 29% year-over-year growth Significant value created across strategic healthcare asset portfolio Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2026, and highlighted select corporate progress and achievements.

    5/6/26 4:05:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress

    Generated $63.4 million in revenue from durable royalties portfolio IST achieved U.S. net product sales of $29.9 million, representing 52% year-over-year growth Strengthened product portfolio with U.S. launch of ZEVTERA® Announced $125 million share repurchase program Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2025, and highlighted select corporate progress and achieve

    11/5/25 4:05:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

    Strong royalties portfolio performance with $67.3 million in revenue IST achieved U.S. net product sales of $29.0 million, reflecting 54% year-over-year growth ZEVTERA (ceftobiprole medocaril sodium, for injection) launched in the U.S. Zoliflodacin NDA accepted by FDA with Priority Review; PDUFA date set for December 15, 2025 Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30,

    8/6/25 4:05:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Innoviva Inc.

    SC 13D/A - Innoviva, Inc. (0001080014) (Filed by)

    11/14/24 4:17:40 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Innoviva Inc.

    SC 13G - Innoviva, Inc. (0001080014) (Subject)

    5/13/24 1:58:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Innoviva Inc.

    SC 13D - Innoviva, Inc. (0001080014) (Subject)

    5/8/24 3:38:11 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care